Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 22.5 | 68 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 27.0 | 59 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 22.0 | 52 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 23.0 | 66 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 27.0 | 46 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 22.0 | 48 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IFN-a2 | 23.0 | 47 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 40.5 | 50 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 36.0 | 71 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 33.0 | 58 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 39.0 | 48 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 43.0 | 77 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 39.0 | 68 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 37.5 | 42 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 40.5 | 62 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 42.0 | 64 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 44.0 | 60 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 36.5 | 40 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IFN-a2 | 42.0 | 51 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 24.0 | 61 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 21.0 | 63 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 22.0 | 53 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 25.0 | 59 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 25.0 | 59 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-a2 | 23.0 | 54 |